Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer based on clinical evidence and expert consensus. NCCN Panel guidance on treatment decisions for patients with localized disease is represented in this version. Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations. The full version of these guidelines, including treatment of patients with advanced disease, can be found online at the NCCN website.
D’AmicoAV, WhittingtonR, MalkowiczSB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer2002;95:281–286.
D’AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer2002;95:281–286.
)| false
ReeseAC, PierorazioPM, HanM, PartinAW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology2012;80:1075–1079.
ReeseACPierorazioPMHanMPartinAW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology2012;80:1075–1079.
)| false
MakarovDV, TrockBJ, HumphreysEB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology2007;69:1095–1101.
MakarovDVTrockBJHumphreysEB. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology2007;69:1095–1101.
)| false
KattanMW, EasthamJA, WheelerTM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003;170:1792–1797.
KattanMWEasthamJAWheelerTM. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol2003;170:1792–1797.
)| false
Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed March 24, 2014.
Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed March 24, 2014.
)| false
StephensonAJ, ScardinoPT, EasthamJA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006;98:715–717.
StephensonAJScardinoPTEasthamJA. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst2006;98:715–717.
)| false
StephensonAJ, KattanMW, EasthamJA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol2009;27:4300–4305.
StephensonAJKattanMWEasthamJA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol2009;27:4300–4305.
)| false
GraefenM, HaeseA, PichlmeierU. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol2001;165:857–863.
GraefenMHaeseAPichlmeierU. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol2001;165:857–863.
)| false
OhoriM, KattanMW, KohH. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol2004;171:1844–1849; discussion 1849.
OhoriMKattanMWKohH. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol2004;171:1844–1849; discussion 1849.
)| false
SteuberT, GraefenM, HaeseA. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol2006;175:939–944; discussion 944.
SteuberTGraefenMHaeseA. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol2006;175:939–944; discussion 944.
)| false
BrigantiA, ChunFK, SaloniaA. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol2007;51:112–119; discussion 119-120.
BrigantiAChunFKSaloniaA. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol2007;51:112–119; discussion 119-120.
)| false
KattanMW, PottersL, BlaskoJC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology2001;58:393–399.
KattanMWPottersLBlaskoJC. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology2001;58:393–399.
)| false
JeldresC, SuardiN, WalzJ. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol2008;54:1306–1313.
JeldresCSuardiNWalzJ. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol2008;54:1306–1313.
)| false
LeeSJ, LindquistK, SegalMR, CovinskyKE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA2006;295:801–808.
LeeSJLindquistKSegalMRCovinskyKE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA2006;295:801–808.
)| false
StephensonAJ, ScardinoPT, KattanMW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol2007;25:2035–2041.
StephensonAJScardinoPTKattanMW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol2007;25:2035–2041.
)| false
DearnaleyDP, KhooVS, NormanAR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet1999;353:267–272.
DearnaleyDPKhooVSNormanAR. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet1999;353:267–272.
)| false
D’AmicoAV, MoulJW, CarrollPR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003;95:1376–1383.
D’AmicoAVMoulJWCarrollPR. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003;95:1376–1383.
)| false
JohanssonJE, HolmbergL, JohanssonS. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA1997;277:467–471.
JohanssonJEHolmbergLJohanssonS. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA1997;277:467–471.
)| false
SakrWA, GrignonDJ, CrissmanJD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo1994;8:439–443.
SakrWAGrignonDJCrissmanJD. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo1994;8:439–443.
)| false
ThompsonIM, PaulerDK, GoodmanPJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004;350:2239–2246.
ThompsonIMPaulerDKGoodmanPJ. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004;350:2239–2246.
)| false
AndrioleGL, CrawfordED, GrubbRL3rd. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012;104:125–132.
AndrioleGLCrawfordEDGrubbRL3rd. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012;104:125–132.
)| false
MillerDC, GruberSB, HollenbeckBK. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst2006;98:1134–1141.
MillerDCGruberSBHollenbeckBK. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst2006;98:1134–1141.
)| false
DraismaG, EtzioniR, TsodikovA. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst2009;101:374–383.
DraismaGEtzioniRTsodikovA. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst2009;101:374–383.
)| false
DraismaG, BoerR, OttoSJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst2003;95:868–878.
DraismaGBoerROttoSJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst2003;95:868–878.
)| false
ChunFK, HaeseA, AhyaiSA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer2008;113:701–709.
ChunFKHaeseAAhyaiSA. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer2008;113:701–709.
)| false
BastianPJ, CarterBH, BjartellA. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol2009;55:1321–1330.
BastianPJCarterBHBjartellA. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol2009;55:1321–1330.
)| false
SundiD, RossAE, HumphreysEB. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?J Clin Oncol2013;31:2991–2997.
SundiDRossAEHumphreysEB. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?J Clin Oncol2013;31:2991–2997.
)| false
CarterHB, KettermannA, WarlickC. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol2007;178:2359–2364; discussion 2364-2355.
CarterHBKettermannAWarlickC. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol2007;178:2359–2364; discussion 2364-2355.
)| false
KlotzL, ZhangL, LamA. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2010;28:126–131.
KlotzLZhangLLamA. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2010;28:126–131.
)| false
SheridanTB, CarterHB, WangW. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol2008;179:901–904; discussion 904-905.
SheridanTBCarterHBWangW. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol2008;179:901–904; discussion 904-905.
)| false
TosoianJJ, TrockBJ, LandisP. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol2011;29:2185–2190.
TosoianJJTrockBJLandisP. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol2011;29:2185–2190.
)| false
LoblawA, ZhangL, LamA. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol2010;184:1942–1946.
LoblawAZhangLLamA. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol2010;184:1942–1946.
)| false
RossAE, LoebS, LandisP. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol2010;28:2810–2816.
RossAELoebSLandisP. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol2010;28:2810–2816.
)| false
FelicianoJ, TeperE, FerrandinoM. The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis?J Urol2008;179:952–955; discussion 955.
FelicianoJTeperEFerrandinoM. The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis?J Urol2008;179:952–955; discussion 955.
)| false
FujitaK, LandisP, McNeilBK, PavlovichCP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol2009;182:2664–2669.
FujitaKLandisPMcNeilBKPavlovichCP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol2009;182:2664–2669.
)| false
PierorazioPM, RossAE, LinBM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int2012;110:1122–1128.
PierorazioPMRossAELinBM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int2012;110:1122–1128.
)| false
ChadeDC, EasthamJ, GraefenM. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol2012;61:961–971.
ChadeDCEasthamJGraefenM. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol2012;61:961–971.
)| false
KleinEA, BiancoFJ, SerioAM. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol2008;179:2212–2216; discussion 2216-2217.
KleinEABiancoFJSerioAM. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol2008;179:2212–2216; discussion 2216-2217.
)| false
NamRK, CheungP, HerschornS. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol2014;15:223–231.
NamRKCheungPHerschornS. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol2014;15:223–231.
)| false
DavisJW, ChangDW, ChevrayP. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol2009;55:1135–1143.
DavisJWChangDWChevrayP. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol2009;55:1135–1143.
)| false
MastersonTA, BiancoFJJr., VickersAJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol2006;175:1320–1324; discussion 1324-1325.
MastersonTABiancoFJJr.VickersAJ. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol2006;175:1320–1324; discussion 1324-1325.
)| false
AllafME, PalapattuGS, TrockBJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol2004;172:1840–1844.
AllafMEPalapattuGSTrockBJ. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol2004;172:1840–1844.
)| false
BaderP, BurkhardFC, MarkwalderR, StuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?J Urol2003;169:849–854.
BaderPBurkhardFCMarkwalderRStuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?J Urol2003;169:849–854.
)| false
DaneshmandS, QuekML, SteinJP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol2004;172:2252–2255.
DaneshmandSQuekMLSteinJP. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol2004;172:2252–2255.
)| false
HanlonAL, Watkins BrunerD, PeterR, HanksGE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys2001;49:51–59.
HanlonALWatkins BrunerDPeterRHanksGE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys2001;49:51–59.
)| false
KoperPC, StroomJC, van PuttenWL. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys1999;43:727–734.
KoperPCStroomJCvan PuttenWL. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys1999;43:727–734.
)| false
MichalskiJM, BaeK, RoachM. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys2010;76:14–22.
MichalskiJMBaeKRoachM. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys2010;76:14–22.
)| false
ZelefskyMJ, LevinEJ, HuntM. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2008;70:1124–1129.
ZelefskyMJLevinEJHuntM. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2008;70:1124–1129.
)| false
JaniAB, SuA, CorreaD, GratzleJ. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis2007;10:82–86.
JaniABSuACorreaDGratzleJ. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis2007;10:82–86.
)| false
PeetersST, HeemsbergenWD, KoperPC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol2006;24:1990–1996.
PeetersSTHeemsbergenWDKoperPC. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol2006;24:1990–1996.
)| false
PollackA, ZagarsGK, StarkschallG. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys2002;53:1097–1105.
PollackAZagarsGKStarkschallG. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys2002;53:1097–1105.
)| false
ZietmanAL, DeSilvioML, SlaterJD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA2005;294:1233–1239.
ZietmanALDeSilvioMLSlaterJD. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA2005;294:1233–1239.
)| false
KubanDA, TuckerSL, DongL. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008;70:67–74.
KubanDATuckerSLDongL. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008;70:67–74.
)| false
ArcangeliS, StrigariL, GomelliniS. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys2012;84:1172–1178.
ArcangeliSStrigariLGomelliniS. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys2012;84:1172–1178.
)| false
PotoskyAL, DavisWW, HoffmanRM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst2004;96:1358–1367.
PotoskyALDavisWWHoffmanRM. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst2004;96:1358–1367.
)| false
NguyenPL, D’AmicoAV, LeeAK, SuhWW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer2007;110:1417–1428.
NguyenPLD’AmicoAVLeeAKSuhWW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer2007;110:1417–1428.
)| false
CritzFA, BentonJB, ShrakeP, MerlinML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol2013;189:878–883.
CritzFABentonJBShrakePMerlinML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol2013;189:878–883.
)| false
BollaM, Van TienhovenG, WardeP. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol2010;11:1066–1073.
BollaMVan TienhovenGWardeP. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol2010;11:1066–1073.
)| false
PilepichMV, WinterK, LawtonCA. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys2005;61:1285–1290.
PilepichMVWinterKLawtonCA. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys2005;61:1285–1290.
)| false
WidmarkA, KleppO, SolbergA. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet2009;373:301–308.
WidmarkAKleppOSolbergA. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet2009;373:301–308.
)| false
DasuA. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?Clin Oncol (R Coll Radiol)2007;19:289–301.
DasuA. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?Clin Oncol (R Coll Radiol)2007;19:289–301.
)| false
BuyyounouskiMK, PriceRAJr., HarrisEE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys2010;76:1297–1304.
BuyyounouskiMKPriceRAJr.HarrisEE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys2010;76:1297–1304.
)| false
MadsenBL, HsiRA, PhamHT. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys2007;67:1099–1105.
MadsenBLHsiRAPhamHT. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys2007;67:1099–1105.
)| false
ChenLN, SuyS, UhmS. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol2013;8:58.
ChenLNSuySUhmS. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol2013;8:58.
)| false
KatzAJ, SantoroM, DiblasioF, AshleyR. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol2013;8:118.
KatzAJSantoroMDiblasioFAshleyR. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol2013;8:118.
)| false
KingCR, FreemanD, KaplanI. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol2013;109:217–221.
KingCRFreemanDKaplanI. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol2013;109:217–221.
)| false
BrachmanDG, ThomasT, HilbeJ, BeyerDC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys2000;48:111–117.
BrachmanDGThomasTHilbeJBeyerDC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys2000;48:111–117.
)| false
EadeTN, HorwitzEM, RuthK. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys2008;71:338–345.
EadeTNHorwitzEMRuthK. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys2008;71:338–345.
)| false
NagS, BiceW, DeWyngaertK. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys2000;46:221–230.
NagSBiceWDeWyngaertK. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys2000;46:221–230.
)| false
Al-SalihiO, MitraA, PayneH. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis2006;9:370–373.
Al-SalihiOMitraAPayneH. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis2006;9:370–373.
)| false
FangFM, WangYM, WangCJ. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol2008;38:474–479.
FangFMWangYMWangCJ. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol2008;38:474–479.
)| false
PietersBR, van de KamerJB, van HertenYR. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol2008;88:46–52.
PietersBRvan de KamerJBvan HertenYR. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol2008;88:46–52.
)| false
SoumarovaR, HomolaL, PerkovaH, StursaM. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori2007;93:37–44.
SoumarovaRHomolaLPerkovaHStursaM. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori2007;93:37–44.
)| false
SathyaJR, DavisIR, JulianJA. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol2005;23:1192–1199.
SathyaJRDavisIRJulianJA. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol2005;23:1192–1199.
)| false
HoskinPJ, MotohashiK, BownesP. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol2007;84:114–120.
HoskinPJMotohashiKBownesP. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol2007;84:114–120.
)| false
ShenX, KeithSW, MishraMV. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys2012;83:1154–1159.
ShenXKeithSWMishraMV. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys2012;83:1154–1159.
)| false
BittnerN, MerrickGS, ButlerWM. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy2012;11:250–255.
BittnerNMerrickGSButlerWM. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy2012;11:250–255.
)| false
Martinez-MongeR, MorenoM, CiervideR. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys2012;82:e469–476.
Martinez-MongeRMorenoMCiervideR. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys2012;82:e469–476.
)| false
D’AmicoAV, MoranBJ, BraccioforteMH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol2009;27:3923–3928.
D’AmicoAVMoranBJBraccioforteMH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol2009;27:3923–3928.
)| false
DemanesDJ, BrandtD, SchourL, HillDR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol2009;32:342–347.
DemanesDJBrandtDSchourLHillDR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol2009;32:342–347.
)| false
DattoliM, WallnerK, TrueL. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol2010;2010:471375.
DattoliMWallnerKTrueL. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol2010;2010:471375.
)| false
VargasC, GhilezanM, HollanderM. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol2005;174:882–887.
VargasCGhilezanMHollanderM. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol2005;174:882–887.
)| false
YuJB, SoulosPR, HerrinJ. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst2013;105:25–32.
YuJBSoulosPRHerrinJ. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst2013;105:25–32.
)| false
CoenJJ, PalyJJ, NiemierkoA. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2012;82:e201–209.
CoenJJPalyJJNiemierkoA. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2012;82:e201–209.
)| false
AllenAM, PawlickiT, DongL. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol2012;103:8–11.
AllenAMPawlickiTDongL. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol2012;103:8–11.
)| false
BahnD, de Castro AbreuAL, GillIS. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol2012;62:55–63.
BahnDde Castro AbreuALGillIS. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol2012;62:55–63.)| false
DonnellyBJ, SalikenJC, BrasherPM. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer2010;116:323–330.
DonnellyBJSalikenJCBrasherPM. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer2010;116:323–330.
)| false
RobinsonJW, DonnellyBJ, SieverJE. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer2009;115:4695–4704.
RobinsonJWDonnellyBJSieverJE. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer2009;115:4695–4704.
)| false
ChinJL, Al-ZahraniAA, Autran-GomezAM. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol2012;188:1170–1175.
ChinJLAl-ZahraniAAAutran-GomezAM. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol2012;188:1170–1175.
)| false
Lu-YaoGL, AlbertsenPC, MooreDF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA2008;300:173–181.
Lu-YaoGLAlbertsenPCMooreDF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA2008;300:173–181.
)| false
D’AmicoAV, ChenMH, RenshawAA. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA2008;299:289–295.
D’AmicoAVChenMHRenshawAA. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA2008;299:289–295.
)| false
DenhamJW, SteiglerA, LambDS. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol2011;12:451–459.
DenhamJWSteiglerALambDS. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol2011;12:451–459.)| false
HorwitzEM, BaeK, HanksGE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol2008;26:2497–2504.
HorwitzEMBaeKHanksGE. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol2008;26:2497–2504.
)| false
SouhamiL, BaeK, PilepichM, SandlerH. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol2009;27:2137–2143.
SouhamiLBaeKPilepichMSandlerH. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol2009;27:2137–2143.
)| false
MessingEM, ManolaJ, YaoJ. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol2006;7:472–479.
MessingEMManolaJYaoJ. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol2006;7:472–479.
)| false
LoblawDA, VirgoKS, NamR. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2007;25:1596–1605.
LoblawDAVirgoKSNamR. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2007;25:1596–1605.
)| false
McLeodDG, SeeWA, KlimbergI. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol2006;176:75–80.
McLeodDGSeeWAKlimbergI. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol2006;176:75–80.
)| false
BrigantiA, PassoniN, FerrariM. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol2010;57:551–558.
BrigantiAPassoniNFerrariM. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol2010;57:551–558.
)| false
WolfJSJr., CherM, Dall’eraM. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol1995;153:993–999.
WolfJSJr.CherMDall’eraM. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol1995;153:993–999.
)| false
DickinsonL, AhmedHU, AllenC. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol2011;59:477–494.
DickinsonLAhmedHUAllenC. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol2011;59:477–494.
)| false
ThompsonIM, TangenCM, ParadeloJ. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol2009;181:956–962.
ThompsonIMTangenCMParadeloJ. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol2009;181:956–962.
)| false
SwansonGP, GoldmanB, TangenCM. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol2008;180:2453–2457; discussion 2458.
SwansonGPGoldmanBTangenCM. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol2008;180:2453–2457; discussion 2458.
)| false
Van der KwastTH, BollaM, Van PoppelH. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol2007;25:4178–4186.
Van der KwastTHBollaMVan PoppelH. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol2007;25:4178–4186.
)| false
WiegelT, BottkeD, SteinerU. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol2009;27:2924–2930.
WiegelTBottkeDSteinerU. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol2009;27:2924–2930.
)| false
Da PozzoLF, CozzariniC, BrigantiA. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol2009;55:1003–1011.
Da PozzoLFCozzariniCBrigantiA. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol2009;55:1003–1011.
)| false
